1-{6-hydroxy-indanyl}-4-acetyl-piperazine | 935248-13-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 1-{6-hydroxy-indanyl}-4-acetyl-piperazine
• CAS: 935248-13-8
• 化学式: C₁₅H₂₀N₂O₂
• 分子量: 260.336
• InChiKey: WDSHFLNQPHKBOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.54
• 重原子数：
  19.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  43.78
• 氢给体数：
  1.0
• 氢受体数：
  3.0

反应信息

• 作为反应物：
  描述：

  1-{6-hydroxy-indanyl}-4-acetyl-piperazine 在 四丁基碘化铵 盐酸 、 三乙酰氧基硼氢化钠 、 caesium carbonate 、 溶剂黄146 作用下， 以 乙醇 、 1,2-二氯乙烷 、 乙腈 为溶剂， 反应 102.0h， 生成 1-(6-((5-(4-chlorophenyl)-1,2,4-oxadiazol-3-yl)methoxy)-2,3-dihydro-1H-inden-1-yl)-4-(3,4-dimethylcyclopentyl)piperazine
  参考文献：
  名称：

  A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening

  摘要：

  The synthesis and structure-activity relationships (SAR) of a series of indane and tetralin inhibitors of the type 1 glycine transporter, derived from a high-throughput screening (HTS) hit, are described. Key modifications that reduced the 5HT1B receptor affinity of the HTS hit and the P450 2D6 inhibition of subsequent analogues are delineated. While these modifications led to potent and selective GlyT1 inhibitors, HERG affinity and human microsomal clearance remain an issue for this series of compounds. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.109
• 作为产物：
  描述：

  6-甲氧基-1-茚酮 在 四丁基碘化铵 sodium tetrahydroborate 、 氯化亚砜 、 三溴化硼 、 potassium carbonate 作用下， 以 甲醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 32.5h， 生成 1-{6-hydroxy-indanyl}-4-acetyl-piperazine
  参考文献：
  名称：

  A novel, non-substrate-based series of glycine type 1 transporter inhibitors derived from high-throughput screening

  摘要：

  The synthesis and structure-activity relationships (SAR) of a series of indane and tetralin inhibitors of the type 1 glycine transporter, derived from a high-throughput screening (HTS) hit, are described. Key modifications that reduced the 5HT1B receptor affinity of the HTS hit and the P450 2D6 inhibition of subsequent analogues are delineated. While these modifications led to potent and selective GlyT1 inhibitors, HERG affinity and human microsomal clearance remain an issue for this series of compounds. (c) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.12.109